Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.65 CAD | -1.69% | -6.06% | +17.72% |
08/04 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
14/03 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Sales 2024 * | 64.08M 87.43M 5.34B | Sales 2025 * | 73.43M 100M 6.12B | Capitalization | 108M 148M 9.03B |
---|---|---|---|---|---|
Net income 2024 * | -20M -27.29M -1.67B | Net income 2025 * | -17M -23.2M -1.42B | EV / Sales 2024 * | 1.69 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.47 x |
P/E ratio 2024 * |
-6.33
x | P/E ratio 2025 * |
-9.44
x | Employees | 91 |
Yield 2024 * |
4.36% | Yield 2025 * |
-
| Free-Float | 99.51% |
Latest transcript on HLS Therapeutics Inc.
1 day | -1.69% | ||
1 week | -6.06% | ||
Current month | +16.25% | ||
1 month | +16.25% | ||
3 months | +13.69% | ||
6 months | -1.90% | ||
Current year | +17.72% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 56 | 01/23/01 |
John Hanna
DFI | Director of Finance/CFO | - | 22/23/22 |
Ryan Lennox
CMP | Compliance Officer | 43 | 07/18/07 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Welborn
CHM | Chairman | 46 | 18/21/18 |
Laura Brege
BRD | Director/Board Member | 66 | 21/19/21 |
John Hanna
DFI | Director of Finance/CFO | - | 22/23/22 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 4.65 | -1.69% | 700 |
25/24/25 | 4.73 | -0.42% | 4,512 |
24/24/24 | 4.75 | 0.00% | 3,900 |
23/24/23 | 4.75 | 0.00% | 2,000 |
22/24/22 | 4.75 | -4.04% | 4,554 |
Delayed Quote Toronto S.E., April 27, 2024 at 12:35 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.72% | 108M | |
+17.35% | 71.39B | |
+2.39% | 25.1B | |
-1.47% | 8.59B | |
+6.69% | 8.19B | |
-20.96% | 7.91B | |
+0.49% | 4.54B | |
+17.12% | 4.31B | |
-2.61% | 3.86B | |
+22.08% | 3.64B |
- Stock Market
- Equities
- HLS Stock